MKX and colorectal carcinoma: The subgroup of CRC patients with high MKX expression status had significantly better OS (HR = 0.22; 95%CI = (0.07–0.7); p = 0.01) and DSS (HR = 0.21; 95%CI = (0.07–0.66); p = 0.008) survival (Figure 6).